{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:29:21Z","timestamp":1772119761922,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Karanata state pharmacy council, Bangalore, Karnataka"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11030-025-11159-w","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T09:32:02Z","timestamp":1742203922000},"page":"3449-3464","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Probing the dark chemical matter against PDE4 for the management of psoriasis using in silico, in vitro and in vivo approach"],"prefix":"10.1007","volume":"29","author":[{"given":"B.","family":"Swapna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satvik","family":"Kotha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divakar","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddamsetty","family":"Ramachandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aruna","family":"Acharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"11159_CR1","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12710","author":"K Reich","year":"2015","unstructured":"Reich K, Papp KA, Matheson RT et al (2015) Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis. Exp Dermatol. https:\/\/doi.org\/10.1111\/exd.12710","journal-title":"Exp Dermatol"},{"key":"11159_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13071064","author":"JC Tseng","year":"2021","unstructured":"Tseng JC, Chang YC, Huang CM et al (2021) Therapeutic development based on the immunopathogenic mechanisms of psoriasis. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics13071064","journal-title":"Pharmaceutics"},{"key":"11159_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.crphar.2021.100041","author":"H Jain","year":"2021","unstructured":"Jain H, Bhat AR, Dalvi H et al (2021) Repurposing approved therapeutics for new indication: Addressing unmet needs in psoriasis treatment. Curr Res Pharmacol Drug Discov. https:\/\/doi.org\/10.1016\/j.crphar.2021.100041","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"11159_CR4","doi-asserted-by":"publisher","DOI":"10.2147\/PTT.S294173","author":"HB Abdallah","year":"2021","unstructured":"Abdallah HB, Johansen C, Iversen L (2021) Key signaling pathways in psoriasis: recent insights from antipsoriatic therapeutics. Psoriasis: Targets Ther. https:\/\/doi.org\/10.2147\/PTT.S294173","journal-title":"Psoriasis: Targets Ther"},{"key":"11159_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00123","author":"VK Raker","year":"2016","unstructured":"Raker VK, Becker C, Steinbrink K (2016) The cAMP pathway as a therapeutic target in autoimmune and inflammatory diseases. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2016.00123","journal-title":"Front Immunol"},{"key":"11159_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2009.00458.x","author":"M Grandoch","year":"2010","unstructured":"Grandoch M, Roscioni SS, Schmidt M (2010) The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br J Pharmacol. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00458.x","journal-title":"Br J Pharmacol"},{"key":"11159_CR7","doi-asserted-by":"publisher","DOI":"10.1042\/0264-6021:3470571","author":"SJ MacKenzie","year":"2000","unstructured":"MacKenzie SJ, Houslay MD (2000) Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem J. https:\/\/doi.org\/10.1042\/0264-6021:3470571","journal-title":"Biochem J"},{"key":"11159_CR8","first-page":"105","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala L (2015) Otezla (Apremilast), an oral PDE-4 inhibitor, receives FDA approval for the treatment of patients with active psoriatic arthritis and plaque psoriasis. Am Health Drug Benefits 8:105\u2013110","journal-title":"Am Health Drug Benefits"},{"key":"11159_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.01.052","author":"J Crowley","year":"2017","unstructured":"Crowley J, Tha\u00e7i D, Joly P et al (2017) Long-term safety and tolerability of apremilast in patients with psoriasis: pooled safety analysis for \u2265156 weeks from 2 phase 3, randomised, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2017.01.052","journal-title":"J Am Acad Dermatol"},{"key":"11159_CR10","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01560","author":"F Ballante","year":"2019","unstructured":"Ballante F, Rudling A, Zeifman A et al (2019) Docking finds GPCR ligands in dark chemical matter. J Med Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01560","journal-title":"J Med Chem"},{"key":"11159_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4787","author":"N Bray","year":"2015","unstructured":"Bray N (2015) Shedding light on the dark chemical matter. Nat Rev Drug Discov. https:\/\/doi.org\/10.1038\/nrd4787","journal-title":"Nat Rev Drug Discov"},{"key":"11159_CR12","doi-asserted-by":"publisher","DOI":"10.1039\/D0RA04922K","author":"MG Santib\u00e1\u00f1ez-Mor\u00e1n","year":"2020","unstructured":"Santib\u00e1\u00f1ez-Mor\u00e1n MG, L\u00f3pez-L\u00f3pez E, Prieto-Mart\u00ednez FD et al (2020) Consensus virtual screening of dark chemical matter and food chemicals uncover potential inhibitors of SARS-CoV-2 main protease. RSC Adv. https:\/\/doi.org\/10.1039\/D0RA04922K","journal-title":"RSC Adv"},{"key":"11159_CR13","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c02058","author":"Z Song","year":"2022","unstructured":"Song Z, Huang YY, Hou KQ et al (2022) Discovery and structural optimization of toddacoumalone derivatives as novel PDE4 inhibitors for the topical treatment of psoriasis. J Med Chem. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c02058","journal-title":"J Med Chem"},{"key":"11159_CR14","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2105\/AJPH.88.12.1879-a","volume":"12","author":"GA Wasserman","year":"1998","unstructured":"Wasserman GA, Graziano J, Factor-Litvak P (1998) Wasserman et al. Respond. Am J Public Health 12:1879\u20131880","journal-title":"Am J Public Health"},{"key":"11159_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2018.00023","author":"AC Kaushik","year":"2018","unstructured":"Kaushik AC, Kumar S, Wei DQ, Sahi S (2018) Structure-based virtual screening studies to identify novel potential compounds for GPR142 and their relative dynamic analysis analysis for the study of type 2 diabetes. Front chem. https:\/\/doi.org\/10.3389\/fchem.2018.00023","journal-title":"Front chem"},{"key":"11159_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/s0887-2333(01)00014-5","author":"RJ Gonzalez","year":"2001","unstructured":"Gonzalez RJ, Tarloff JB (2001) Evaluation of hepatic sub-cellular fractions for alamar blue and MTT reductase activity. Toxicol In vitro. https:\/\/doi.org\/10.1016\/s0887-2333(01)00014-5","journal-title":"Toxicol In vitro"},{"key":"11159_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2014.12.026","author":"JA Heward","year":"2015","unstructured":"Heward JA, Roux BT, Lindsay MA (2015) Divergent signalling pathways regulate lipopolysaccharide-induced eRNA expression in human monocytic THP1 cells. FEBS Lett. https:\/\/doi.org\/10.1016\/j.febslet.2014.12.026","journal-title":"FEBS Lett"},{"key":"11159_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(93)90011-u","author":"SPM Crouch","year":"1993","unstructured":"Crouch SPM, Kozlowski R, Slater KJ, Fletcher J (1993) The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol. https:\/\/doi.org\/10.1016\/0022-1759(93)90011-u","journal-title":"J Immunol"},{"key":"11159_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12090789","author":"M Jabeen","year":"2020","unstructured":"Jabeen M, Boisgard AS, Danoy A et al (2020) Advanced characterization of imiquimod-induced psoriasis like mouse model. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics12090789","journal-title":"Pharmaceutics"},{"key":"11159_CR20","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrestox.2c00207","author":"L Li","year":"2022","unstructured":"Li L, Lu Z, Liu G, Tang Y, Li W (2022) In silico prediction of human and rat liver microsomal stability via machine learning methods. Chem Res Toxicol. https:\/\/doi.org\/10.1021\/acs.chemrestox.2c00207","journal-title":"Chem Res Toxicol"},{"key":"11159_CR21","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.2c00297","author":"C Lou","year":"2022","unstructured":"Lou C, Yang H, Wang J, Huang M, Li W, Liu G et al (2022) IDL-PPBopt: a strategy for prediction and optimization of human plasma protein binding of compounds via an interpretable deep learning method. J Chem Inf Model. https:\/\/doi.org\/10.1021\/acs.jcim.2c00297","journal-title":"J Chem Inf Model"},{"key":"11159_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-019-0151-1","author":"MC Sorkun","year":"2019","unstructured":"Sorkun MC, Khetan A, Er S (2019) AqSolDB, a curated reference set of aqueous solubility and 2D descriptors for a diverse set of compounds. Sci Data. https:\/\/doi.org\/10.1038\/s41597-019-0151-1","journal-title":"Sci Data"},{"key":"11159_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2004.10.004","author":"GL Card","year":"2004","unstructured":"Card GL, England BP, Suzuki Y, Fong D et al (2004) Structural basis for the activity of drugs that inhibit phosphodiesterases. Structure. https:\/\/doi.org\/10.1016\/j.str.2004.10.004","journal-title":"Structure"},{"key":"11159_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/s0969-2126(03)00123-0","author":"Q Huai","year":"2003","unstructured":"Huai Q, Wang H, Sun Y et al (2003) Three-dimensional structures of PDE4DD in complex with roliprams and implication on inhibitor selectivity. Structure. https:\/\/doi.org\/10.1016\/s0969-2126(03)00123-0","journal-title":"Structure"},{"key":"11159_CR25","doi-asserted-by":"publisher","DOI":"10.1021\/jm100112j","author":"C Bissantz","year":"2010","unstructured":"Bissantz C, Kuhn B, Stahl M (2010) A medicinal chemist\u2019s guide to molecular interactions. J Med Chem. https:\/\/doi.org\/10.1021\/jm100112j","journal-title":"J Med Chem"},{"key":"11159_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/prot.21818","author":"B Seebeck","year":"2007","unstructured":"Seebeck B, Reulecke I, K\u00e4mper A, Rarey M (2007) Modeling of metal interaction geometries for protein\u2013ligand docking. Proteins: Struct Funct Bioinf. https:\/\/doi.org\/10.1002\/prot.21818","journal-title":"Proteins: Struct Funct Bioinf"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11159-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11159-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11159-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T07:52:59Z","timestamp":1757145179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11159-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["11159"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11159-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5091663\/v1","asserted-by":"object"}]},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"15 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}